<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01336530</url>
  </required_header>
  <id_info>
    <org_study_id>X-03030-3277</org_study_id>
    <secondary_id>2009-014441-93</secondary_id>
    <nct_id>NCT01336530</nct_id>
  </id_info>
  <brief_title>Tepilta® Versus Oxetacaine, Antacids and Placebo</brief_title>
  <official_title>Clinical Trial to Assess the Efficacy of Fixed Combination Product Tepilta® in the Treatment of Radiation-induced Oesophagitis Compared to Its Active Ingredients Oxetacaine and Antacids, and to Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MEDA Pharma GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Trium Analysis Online GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ICON plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinipace Worldwide</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MEDA Pharma GmbH &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, double-blind, placebo-controlled, therapeutic confirmatory multicentre
      trial with 4 parallel treatment groups. The design is adaptive group-sequential with two
      interim analyses, possible sample size re-estimation after the first or second interim
      analysis and drop-the-loser approach. The study design was primarily chosen to show superior
      efficacy of Tepilta® compared to the single components and to placebo. Evaluation of safety
      is a secondary objective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tepilta® Suspension is indicated for treatment of pain in the upper digestive system induced
      by radiation therapy, in particular for radiation-induced oesophagitis.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study stopped prematurely due to and administrative reasons, not based on grounds of
    safety.
  </why_stopped>
  <start_date type="Actual">April 2011</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from randomisation to requirement of additional systemic pain medication for oesophagitis (ASPO).</measure>
    <time_frame>up to 11 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ASPO: WHO analgesic pain ladder</measure>
    <time_frame>up to 11 weeks</time_frame>
    <description>ASPO = Additional systemic pain medication for oesophagitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity recorded on NRS with scores 0-10</measure>
    <time_frame>up to 11 weeks</time_frame>
    <description>NRS = Numeric Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swallowing disorder recorded on NRS with scores 0-10</measure>
    <time_frame>up to 11 weeks</time_frame>
    <description>NRS = Numeric Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adapted CTCAE grade</measure>
    <time_frame>up to 11 weeks</time_frame>
    <description>CTCAE = Common Terminology Criteria for Adverse Events
Severity of oesophageal symptoms will be evaluated by the investigator according to an adapted CTCAE grading system. In contrast to the original CTCAE classification the adapted version foreseen to be used in this study distinguishes level 2a and 2b.
2a = symptomatic; altered eating/swallowing; oral supplements indicated; requiring predominantly pureed or soft diet, 2b = symptomatic; altered eating/swallowing; oral supplements indicated; requiring predominantly liquid diet.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of artificial nutrition due to radiation-induced oesophagitis</measure>
    <time_frame>up to 11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of interruptions of radiation therapy due to radiation-induced oesophagitis</measure>
    <time_frame>up to 11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of pain medication intake after the end of Radiation Therapy</measure>
    <time_frame>up to 11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss of body weight</measure>
    <time_frame>up to 11 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Radiation-induced Oesophagitis</condition>
  <arm_group>
    <arm_group_label>Tepilta®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxetacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Antacids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxetacaine, aluminium and magnesium hydroxide</intervention_name>
    <description>20mg/10ml oxetacaine, 196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.</description>
    <arm_group_label>Tepilta®</arm_group_label>
    <other_name>Tepilta®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxetacaine</intervention_name>
    <description>20mg/10ml oxetacaine. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.</description>
    <arm_group_label>Oxetacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>magnesium and aluminium hydroxide</intervention_name>
    <description>196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.</description>
    <arm_group_label>Antacids</arm_group_label>
    <other_name>Antacids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Placebo suspension for oral intake 3-6 times per day for a maximum of 11 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female ≥ 18 years.

          2. Score = 0 on NRS for oesophageal pain.

          3. Radiotherapy (RT) or combined radio-chemotherapy (RCT) of a solid tumour in
             head/neck/thorax region. A minimum length of 5 cm of the oesophagus must be included
             in high-dose radiation field.

          4. Duration of RT 5 to 8 weeks.

          5. Single radiation dosage of fractionated RT 1.8 to 2.0 Gy/day, of intensity-modulated
             RT (IMRT) 1.5 to 2.3 Gy/day, each for 5 days a week (single frequency deviations are
             allowed presuming that intended duration of RT remains 5 to 8 weeks).

          6. First radiation in the intended radiation area.

          7. Written informed consent.

             Randomisation criteria:

          8. Appearance of oesophageal pain as follows: Score ≥ 2 on Numeric Rating Scale (NRS) for
             pain during main daily meals is reached at least once.

          9. At least 20 Gy of the dose of radiation therapy in oesophageal area remaining.

         10. Oesophageal symptoms of grade ≤ 2a according to the adapted Common Terminology
             Criteria for Adverse Events CTCAE.

        Exclusion Criteria:

          1. History of allergic reaction to the study medication or its excipients (i.e. aluminium
             or magnesium hydroxide, oxetacaine, any other ingredient of study medication).

          2. Pregnancy, breast-feeding or planned pregnancy during the study.

          3. Known hypermagnesaemia.

          4. Known hypophosphataemia.

          5. Clinically significant obstipation, as judged by the investigator.

          6. Acute appendicitis.

          7. Total intended radiation dose at lips and the anterior oral cavity &gt; 60% of total
             intended radiation dose at the swallowing process (pharynx, oesophagus).

          8. Hyper-fractionated RT.

          9. Intended naso-gastral tubes.

         10. Primary tumour of the cranial base, brain, oral cavity, lips, naso-pharynx, para-nasal
             sinuses.

         11. Known bone metastases.

         12. Reflux oesophagitis 3 months prior to the study.

         13. Continuous systemic pain treatment at the beginning of RT. Systemic pain medication
             for oesophagitis prior to randomisation must not be taken.

         14. Concomitant treatment with tetracyclines, cinolone derivatives (ciprofloxacin,
             ofloxacin, enoxacin, norfloxacin), cheno-desoxycholic acid, sodium fluoride, local
             anaesthetics (other than those used as study medication).

         15. Patients relying on levothyroxine after resection of thyroid carcinoma being
             hypothyroid and patients relying on levothyroxine due to other reasons not being
             euthyroid.

         16. Artificial nutrition at the beginning of radiation.

         17. Drug (licit and illicit) or alcohol abuse which would interfere with the patient's
             proper completion of the study.

         18. Exposure to an investigational product within the last 4 weeks, simultaneous exposure
             to another investigational product.

         19. Lack of ability or willingness to give informed consent.

         20. Anticipated non-availability for study visits / procedures.

         21. Lack of ability or willingness to keep patient's diary.

         22. Lack of willingness to have personal study related data collected, archived or
             transmitted according to the protocol.

         23. Vulnerable subjects.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Bruns, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ursula Petzold, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>MEDA Pharma GmbH &amp; Co. KG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landeskrankenhaus Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <zip>6807</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Strahlentherapie-Radioonkologie</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RADIO LOG Strahlentherapie Altötting</name>
      <address>
        <city>Altötting</city>
        <zip>84503</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>please contact Dr. Ingrid Schwienhorst/MEDA for details</name>
      <address>
        <city>Bad Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VIVANTES Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strahlenheilkunde Westend</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franziskus Hospital</name>
      <address>
        <city>Bielefeld</city>
        <zip>33615</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Hämatologie, Onkologie &amp; Palliativmedizin</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strahlentherapie Bonn-Rhein-Sieg</name>
      <address>
        <city>Bonn</city>
        <zip>53177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Braunschweig GmbH</name>
      <address>
        <city>Braunschweig</city>
        <zip>38114</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strahlentherapie Coesfeld</name>
      <address>
        <city>Coesfeld</city>
        <zip>48653</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaftskrankenhaus Dortmund</name>
      <address>
        <city>Dortmund</city>
        <zip>44309</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt (Oder) GmbH</name>
      <address>
        <city>Frankfurt (Oder)</city>
        <zip>15236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest GmbH</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strahlentherapie - Freising</name>
      <address>
        <city>Freising</city>
        <zip>85354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Gummersbach</name>
      <address>
        <city>Gummersbach</city>
        <zip>51643</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale)</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kath. Krankenhaus Marienhospital</name>
      <address>
        <city>Herne</city>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Strahlentherapie und Radioonkologie</name>
      <address>
        <city>Marburg</city>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Maria Hilf GmbH</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Strahlentherapie und Radioonkologie am Klinikum Schwabing</name>
      <address>
        <city>München</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paracelsus-Klinik Osnabrück</name>
      <address>
        <city>Osnabrück</city>
        <zip>49076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paracelsus-Krankenhaus Ruit</name>
      <address>
        <city>Ostfildern</city>
        <zip>73760</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brüderkrankenhaus St. Josef</name>
      <address>
        <city>Paderborn</city>
        <zip>33098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ernst von Bergmann</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prosperhospital Recklinghausen</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45659</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Rostock AöR</name>
      <address>
        <city>Rostock</city>
        <zip>18059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Radioonkologie und Strahlentherapie</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2011</study_first_submitted>
  <study_first_submitted_qc>April 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2011</study_first_posted>
  <last_update_submitted>May 18, 2017</last_update_submitted>
  <last_update_submitted_qc>May 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oesophageal pain</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Combined radio-chemotherapy</keyword>
  <keyword>Oesophageal symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aluminum Hydroxide</mesh_term>
    <mesh_term>Antacids</mesh_term>
    <mesh_term>Magnesium Hydroxide</mesh_term>
    <mesh_term>Anti-Ulcer Agents</mesh_term>
    <mesh_term>Oxethazaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

